Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI23048663 |
Pages: 350 |
Apr 2023 |
The major factors driving the gastric cancer market include increasing prevalence of gastric cancer worldwide, advancements in diagnostic and treatment technologies, increasing healthcare expenditure, and a growing aging population. Moreover, advancements in diagnostic technologies such as endoscopy, biopsy, and imaging techniques have facilitated early detection and diagnosis of gastric cancer, which can improve patient outcomes and survival rates. Treatment options for gastric cancer include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Advances in these treatment options has led to improved outcomes and increase in demand for these treatments. The growing aging population, particularly in developed countries, is also a significant driver of the gastric cancer market, as age is a risk factor for the disease. These factors are anticipated to boost the gastric cancer industry growth in the upcoming years.
However, lack of awareness about gastric cancer is one of the key factors that is expected to restrain the growth of the gastric cancer market. Gastric cancer is not as well-known as other types of cancer, and its symptoms can often be vague and easily mistaken for other less serious conditions. Moreover, there is also a lack of awareness among healthcare professionals about the latest diagnostic and treatment options for gastric cancer. All these factors are projected to hamper the gastric cancer market growth in the upcoming years.
Minimally invasive procedures, such as laparoscopic and robotic-assisted surgery, have been proved to be effective in the treatment of gastric cancer and can offer benefits such as faster recovery time, less pain, and reduced hospital stays. The adoption of these procedures is expected to increase as technology advances and more surgeons become trained in these techniques. The growing awareness and screening programs for gastric cancer is also predicted to provide opportunities for the market players. The gastric cancer market presents several opportunities for growth, including the development of new targeted therapies, the adoption of minimally invasive surgical procedures, and increased awareness and screening programs.
According to regional analysis, the Asia-Pacific gastric cancer market size accounted for the largest market share in 2021, due to the high prevalence of gastric cancer in this region. Gastric cancer is one of the leading causes of cancer-related deaths in Asia-Pacific, with a higher incidence rate compared to other regions across the world.
Gastric cancer, also known as stomach cancer, is a type of cancer that develops in the lining of the stomach. Gastric cancer can be classified into different types based on the location of the tumor in the stomach and the type of cells it affects. The two most common types are adenocarcinoma, which develops in the glandular cells of the stomach lining, and lymphoma, which develops in the immune system cells of the stomach. There are several risk factors that have been identified, including age (most cases occur in people over the age of 50), a family history of stomach cancer, smoking, a diet high in salted or smoked foods, and chronic infection with the bacteria Helicobacter pylori.
The COVID-19 pandemic had a significant impact on the healthcare industry worldwide, including the gastric cancer market. The pandemic disrupted the global supply chain, leading to shortages of raw materials and delay in the delivery of finished products. The pandemic also led to the postponement or cancellation of elective surgeries and other medical procedures, which affected the diagnosis and treatment of gastric cancer patients. Moreover, the covid-19 impact on gastric cancer market had reduced healthcare spending in many countries, as resources had been redirected to pandemic-related measures. This affected the development of new drugs and therapies for gastric cancer, as well as the availability of existing treatments. Many pharmaceutical companies faced challenges in securing the raw materials and components needed to manufacture their products, which resulted in delays in drug production and distribution.
However, despite the challenges posed by the pandemic, the gastric cancer market is expected to continue to grow in the post-pandemic period. This growth is driven by factors such as an aging population, increasing incidence of gastric cancer, and the development of new therapies and treatments.
The increase in prevalence of gastric cancer is expected to drive the demand for new and more effective treatments. Gastric cancer is a major global health problem, with an estimated one million new cases diagnosed each year. Several factors contribute to the increasing incidence of gastric cancer, including aging population, unhealthy lifestyle habits such as smoking and poor dietary choices, and infections with Helicobacter pylori, a bacterium that can cause chronic inflammation of the stomach lining. The development of targeted therapies and immunotherapies, in particular, has proven to be efficient in treating gastric cancer and is expected to drive the market in the upcoming years. The demand for effective treatments is expected to drive growth of the market, particularly in the areas of targeted therapies and immunotherapies.
To know more about global gastric cancer market drivers, get in touch with our analysts here.
The high cost of treating gastric cancer is one of the key factors restraining the growth of the gastric cancer market. The treatment of gastric cancer involves a combination of surgery, chemotherapy, radiation therapy, and targeted therapy. Moreover, the need for ongoing monitoring and follow-up care after treatment can further add to the cost of treatment. The high cost of treatment can also lead to limited access to care, particularly in low- and middle-income countries, where healthcare resources may be limited. This can result in delayed diagnosis and treatment, which can have a negative impact on patient outcomes. All these are the major factors anticipated to hamper the gastric cancer market growth during the forecast period.
The increase in investment in R&D for gastric cancer treatments has led to the discovery of new and more effective treatments, which can help improve patient outcomes. In addition, the rising healthcare expenditure has also led to the development of better diagnostic tools and screening techniques for early detection of gastric cancer, which can lead to better prognosis and survival rates. Furthermore, the increase in prevalence of gastric cancer globally, especially in developing countries, provides a significant opportunity for pharmaceutical companies to expand their market and develop new treatments for this disease. These factors are projected to create several growth opportunities for the key players operating in the market in the future.
To know more about global gastric cancer market opportunities, get in touch with our analysts here.
Based on disease type, the market has been divided into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. Among these, the adenocarcinoma sub-segment accounted for the highest market share in 2021 and is anticipated to show the fastest growth during the forecast period.
Source: Research Dive Analysis
The adenocarcinoma sub-segment accounted for the largest gastric cancer market share in 2021 and is anticipated to witness the fastest growth in 2031. Adenocarcinoma is the most common type of gastric cancer, accounting for approximately 95% of cases worldwide. Gastric cancer incidence rates vary across regions and populations, though the incidence of gastric cancer has been increasing in various regions across the world including Asia-Pacific, Europe, and North America. This is expected to drive demand for treatments and diagnostic tools for adenocarcinoma. There have been advances in the treatment of gastric cancer, including the development of targeted therapies and immunotherapies. These therapies can potentially improve outcomes for patients with adenocarcinoma, which is predicted to drive the market growth.
Based on treatment type, the market has been divided into immunotherapy, targeted therapy, chemotherapy, and radiation therapy and surgery. Among these, the chemotherapy sub-segment accounted for the highest revenue share in 2021.
Source: Research Dive Analysis
The chemotherapy sub-segment accounted for the largest gastric cancer market share in 2021. Gastric cancer, also known as stomach cancer, is a type of cancer that originates in the cells of the stomach. Chemotherapy is one of the main treatments for gastric cancer and involves the use of drugs to kill cancer cells. Chemotherapy works by targeting rapidly dividing cells, including cancer cells. It can be used before or after surgery, or as the primary treatment for advanced gastric cancer. Chemotherapy can also be combined with other treatments, such as radiation therapy and targeted therapy, to increase its effectiveness. These factors are anticipated to boost the growth of the chemotherapy sub-segment during the forecast timeframe.
Based on drug class outlook, the market has been divided into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and others. Among these, the PD-1/PD-L1 inhibitors sub-segment is estimated to show the fastest growth during the forecast period.
Source: Research Dive Analysis
The PD-1/PD-L1 inhibitors sub-segment is estimated to show the fastest growth during the forecast period. PD-1/PD-L1 inhibitors are a type of immunotherapy that can help the body's immune system recognize and attack cancer cells. PD-1/PD-L1 inhibitors work by blocking the interaction between the PD-1 protein on T cells and the PD-L1 protein on cancer cells. This interaction can suppress the immune system's ability to attack cancer cells. By blocking this interaction, PD-1/PD-L1 inhibitors can allow the immune system to mount a more effective response against cancer cells. These factors are anticipated to boost the growth of the PD-1/PD-L1 inhibitors sub-segment during the forecast years.
Based on route of administration, the market has been divided into oral and injectable. Among these, the oral sub-segment accounted for the largest market share in 2021.
Source: Research Dive Analysis
The oral sub-segment accounted for the largest market share in 2021. Gastric cancer is a type of cancer that begins in the stomach and it can affect various parts of the stomach, including the oral segment. The oral segment of the stomach refers to the part of the stomach that is closest to the esophagus. The oral segment growth is driven by the need for early detection and effective treatment options. Early detection is critical for successful treatment outcomes, and there is a growing demand for minimally invasive diagnostic techniques that can accurately detect oral segment gastric cancer at an early stage. These factors are anticipated to boost the growth of oral sub-segment during the forecast period.
Based on distribution channel, the market has been divided into hospital pharmacies, specialty & retail pharmacies, and others. Among these, the specialty & retail pharmacies sub-segment accounted for the largest market share in 2021.
Source: Research Dive Analysis
The specialty & retail pharmacies sub-segment accounted for the largest market share in 2021. Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related deaths globally. Therefore, there is a growing demand for effective treatments for gastric cancer, and specialty and retail pharmacies play a crucial role in the offering these treatments. Specialty pharmacies, in particular, are well-suited for distributing treatments for gastric cancer because they have expertise in managing complex therapies, providing patient education and support, and coordinating with healthcare providers. These factors are anticipated to boost the growth of specialty & retail pharmacies sub-segment in the upcoming years.
The gastric cancer market was investigated across North America, Europe, Asia-Pacific, and LAMEA.
Source: Research Dive Analysis
The Asia-Pacific gastric cancer market analysis accounted for the largest market share in 2021. Asia-Pacific is the largest market for gastric cancer due to several factors such as the high incidence of gastric cancer, a large population, increasing awareness and diagnosis of the disease, and rising healthcare expenditure. Several countries in the region such as Japan, China, South Korea, and India have a high incidence of gastric cancer, which is driving the demand for diagnostic and treatment options. Increasing awareness about gastric cancer and its risk factors among the population, along with the availability of advanced diagnostic technologies such as endoscopy and imaging techniques, is also driving the regional market growth. Furthermore, the increasing healthcare expenditure in the region, especially in emerging countries, is boosting the demand for better treatment options and driving the market growth. These are the key factors anticipated to drive the gastric cancer market in the region during the forecast period.
Investment and agreement are common strategies followed by major market players. For instance, in April 2020, in the U.S., Samsung Bioepis launched ONTRUZANT, a biosimilar version of the reference biologic drug HERCEPTIN, for the treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Source: Research Dive Analysis
Some of the leading gastric cancer market players are Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis, and Bristol Myers Squibb Company.
| Aspect | Particulars |
| Historical Market Estimations | 2020 |
| Base Year for Market Estimation | 2021 |
| Forecast Timeline for Market Projection | 2022-2031 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Disease Type |
|
| Segmentation by Treatment Type |
|
| Segmentation by Drug Class Outlook |
|
| Segmentation by Route of Administration |
|
| Segmentation by Distribution Channel |
|
| Key Companies Profiled |
|
1.Research Methodology
1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach
2.Report Scope
2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on Global Gastric Cancer market
3.Executive Summary
4.Market Overview
4.1.Introduction
4.2.Growth impact forces
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities
4.3.Market value chain analysis
4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors
4.4.Innovation & sustainability matrices
4.4.1.Technology matrix
4.4.2.Regulatory matrix
4.5.Porter’s five forces analysis
4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity
4.6.PESTLE analysis
4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental
4.7.Impact of COVID-19 on Gastric Cancer market
4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario
5.Gastric Cancer Market Analysis, by Disease Type
5.1.Overview
5.2.Adenocarcinoma
5.2.1.Definition, key trends, growth factors, and opportunities
5.2.2.Market size analysis, by region,2021-2031
5.2.3.Market share analysis, by country,2021-2031
5.3.Lymphoma
5.3.1.Definition, key trends, growth factors, and opportunities
5.3.2.Market size analysis, by region,2021-2031
5.3.3.Market share analysis, by country,2021-2031
5.4.Gastrointestinal Stromal Tumor
5.4.1.Definition, key trends, growth factors, and opportunities
5.4.2.Market size analysis, by region,2021-2031
5.4.3.Market share analysis, by country,2021-2031
5.5.Carcinoid Tumor
5.5.1.Definition, key trends, growth factors, and opportunities
5.5.2.Market size analysis, by region,2021-2031
5.5.3.Market share analysis, by country,2021-2031
5.6.Others
5.6.1.Definition, key trends, growth factors, and opportunities
5.6.2.Market size analysis, by region
5.6.3.Market share analysis, by country
5.7.Research Dive Exclusive Insights
5.7.1.Market attractiveness
5.7.2.Competition heatmap
6.Gastric Cancer Market Analysis, by Treatment Type
6.1.Immunotherapy
6.1.1.Definition, key trends, growth factors, and opportunities
6.1.2.Market size analysis, by region,2021-2031
6.1.3.Market share analysis, by country,2021-2031
6.2.Targeted Therapy
6.2.1.Definition, key trends, growth factors, and opportunities
6.2.2.Market size analysis, by region,2021-2031
6.2.3.Market share analysis, by country,2021-2031
6.3.Chemotherapy
6.3.1.Definition, key trends, growth factors, and opportunities
6.3.2.Market size analysis, by region,2021-2031
6.3.3.Market share analysis, by country,2021-2031
6.4.Radiation Therapy and Surgery
6.4.1.Definition, key trends, growth factors, and opportunities
6.4.2.Market size analysis, by region,2021-2031
6.4.3.Market share analysis, by country,2021-2031
6.5.Research Dive Exclusive Insights
6.5.1.Market attractiveness
6.5.2.Competition heatmap
7.Gastric Cancer Market Analysis, by Drug Class Outlook
7.1.PD-1/PD-L1 Inhibitors
7.1.1.Definition, key trends, growth factors, and opportunities
7.1.2.Market size analysis, by region,2021-2031
7.1.3.Market share analysis, by country,2021-2031
7.2.HER2 Antagonists
7.2.1.Definition, key trends, growth factors, and opportunities
7.2.2.Market size analysis, by region,2021-2031
7.2.3.Market share analysis, by country,2021-2031
7.3.VEGFR2 Antagonists
7.3.1.Definition, key trends, growth factors, and opportunities
7.3.2.Market size analysis, by region,2021-2031
7.3.3.Market share analysis, by country,2021-2031
7.4.Others
7.4.1.Definition, key trends, growth factors, and opportunities
7.4.2.Market size analysis, by region,2021-2031
7.4.3.Market share analysis, by country,2021-2031
7.5.Research Dive Exclusive Insights
7.5.1.Market attractiveness
7.5.2.Competition heatmap
8.Gastric Cancer Market Analysis, by Route of Administration
8.1.Oral
8.1.1.Definition, key trends, growth factors, and opportunities
8.1.2.Market size analysis, by region,2021-2031
8.1.3.Market share analysis, by country,2021-2031
8.2.Injectable
8.2.1.Definition, key trends, growth factors, and opportunities
8.2.2.Market size analysis, by region,2021-2031
8.2.3.Market share analysis, by country,2021-2031
8.3.Research Dive Exclusive Insights
8.3.1.Market attractiveness
8.3.2.Competition heatmap
9.Gastric Cancer Market Analysis, by Distribution Channel
9.1.Hospital Pharmacies
9.1.1.Definition, key trends, growth factors, and opportunities
9.1.2.Market size analysis, by region,2021-2031
9.1.3.Market share analysis, by country,2021-2031
9.2.Specialty & Retail Pharmacies
9.2.1.Definition, key trends, growth factors, and opportunities
9.2.2.Market size analysis, by region,2021-2031
9.2.3.Market share analysis, by country,2021-2031
9.3.Others
9.3.1.Definition, key trends, growth factors, and opportunities
9.3.2.Market size analysis, by region,2021-2031
9.3.3.Market share analysis, by country,2021-2031
9.4.Research Dive Exclusive Insights
9.4.1.Market attractiveness
9.4.2.Competition heatmap
10.Gastric Cancer Market, by Region
10.1.North America
10.1.1.U.S.
10.1.1.1.Market size analysis, by Disease Type
10.1.1.2.Market size analysis, by Treatment Type
10.1.1.3.Market size analysis, by Drug Class Outlook
10.1.1.4.Market size analysis, by Route of Administration
10.1.1.5.Market size analysis, by Distribution Channel
10.1.2.Canada
10.1.2.1.Market size analysis, by Disease Type
10.1.2.2.Market size analysis, by Treatment Type
10.1.2.3.Market size analysis, by Drug Class Outlook
10.1.2.4.Market size analysis, by Route of Administration
10.1.2.5.Market size analysis, by Distribution Channel
10.1.3.Mexico
10.1.3.1.Market size analysis, by Disease Type
10.1.3.2.Market size analysis, by Treatment Type
10.1.3.3.Market size analysis, by Drug Class Outlook
10.1.3.4.Market size analysis, by Route of Administration
10.1.3.5.Market size analysis, by Distribution Channel
10.1.4.Research Dive Exclusive Insights
10.1.4.1.Market attractiveness
10.1.4.2.Competition heatmap
10.2.Europe
10.2.1.Germany
10.2.1.1.Market size analysis, by Disease Type
10.2.1.2.Market size analysis, by Treatment Type
10.2.1.3.Market size analysis, by Drug Class Outlook
10.2.1.4.Market size analysis, by Route of Administration
10.2.1.5.Market size analysis, by Distribution Channel
10.2.2.UK
10.2.2.1.Market size analysis, by Disease Type
10.2.2.2.Market size analysis, by Treatment Type
10.2.2.3.Market size analysis, by Drug Class Outlook
10.2.2.4.Market size analysis, by Route of Administration
10.2.2.5.Market size analysis, by Distribution Channel
10.2.3.France
10.2.3.1.Market size analysis, by Disease Type
10.2.3.2.Market size analysis, by Treatment Type
10.2.3.3.Market size analysis, by Drug Class Outlook
10.2.3.4.Market size analysis, by Route of Administration
10.2.3.5.Market size analysis, by Distribution Channel
10.2.4.Spain
10.2.4.1.Market size analysis, by Disease Type
10.2.4.2.Market size analysis, by Treatment Type
10.2.4.3.Market size analysis, by Drug Class Outlook
10.2.4.4.Market size analysis, by Route of Administration
10.2.4.5.Market size analysis, by Distribution Channel
10.2.5.Italy
10.2.5.1.Market size analysis, by Disease Type
10.2.5.2.Market size analysis, by Treatment Type
10.2.5.3.Market size analysis, by Drug Class Outlook
10.2.5.4.Market size analysis, by Route of Administration
10.2.5.5.Market size analysis, by Distribution Channel
10.2.6.Rest of Europe
10.2.6.1.Market size analysis, by Disease Type
10.2.6.2.Market size analysis, by Treatment Type
10.2.6.3.Market size analysis, by Drug Class Outlook
10.2.6.4.Market size analysis, by Route of Administration
10.2.6.5.Market size analysis, by Distribution Channel
10.2.7.Research Dive Exclusive Insights
10.2.7.1.Market attractiveness
10.2.7.2.Competition heatmap
10.3.Asia-Pacific
10.3.1.China
10.3.1.1.Market size analysis, by Disease Type
10.3.1.2.Market size analysis, by Treatment Type
10.3.1.3.Market size analysis, by Drug Class Outlook
10.3.1.4.Market size analysis, by Route of Administration
10.3.1.5.Market size analysis, by Distribution Channel
10.3.2.Japan
10.3.2.1.Market size analysis, by Disease Type
10.3.2.2.Market size analysis, by Treatment Type
10.3.2.3.Market size analysis, by Drug Class Outlook
10.3.2.4.Market size analysis, by Route of Administration
10.3.2.5.Market size analysis, by Distribution Channel
10.3.3.India
10.3.3.1.Market size analysis, by Disease Type
10.3.3.2.Market size analysis, by Treatment Type
10.3.3.3.Market size analysis, by Drug Class Outlook
10.3.3.4.Market size analysis, by Route of Administration
10.3.3.5.Market size analysis, by Distribution Channel
10.3.4.Australia
10.3.4.1.Market size analysis, by Disease Type
10.3.4.2.Market size analysis, by Treatment Type
10.3.4.3.Market size analysis, by Drug Class Outlook
10.3.4.4.Market size analysis, by Route of Administration
10.3.4.5.Market size analysis, by Distribution Channel
10.3.5.South Korea
10.3.5.1.Market size analysis, by Disease Type
10.3.5.2.Market size analysis, by Treatment Type
10.3.5.3.Market size analysis, by Drug Class Outlook
10.3.5.4.Market size analysis, by Route of Administration
10.3.5.5.Market size analysis, by Distribution Channel
10.3.6.Rest of Asia-Pacific
10.3.6.1.Market size analysis, by Disease Type
10.3.6.2.Market size analysis, by Treatment Type
10.3.6.3.Market size analysis, by Drug Class Outlook
10.3.6.4.Market size analysis, by Route of Administration
10.3.6.5.Market size analysis, by Distribution Channel
10.3.7.Research Dive Exclusive Insights
10.3.7.1.Market attractiveness
10.3.7.2.Competition heatmap
10.4.LAMEA
10.4.1.Brazil
10.4.1.1.Market size analysis, by Disease Type
10.4.1.2.Market size analysis, by Treatment Type
10.4.1.3.Market size analysis, by Drug Class Outlook
10.4.1.4.Market size analysis, by Route of Administration
10.4.1.5.Market size analysis, by Distribution Channel
10.4.2.Saudi Arabia
10.4.2.1.Market size analysis, by Disease Type
10.4.2.2.Market size analysis, by Treatment Type
10.4.2.3.Market size analysis, by Drug Class Outlook
10.4.2.4.Market size analysis, by Route of Administration
10.4.2.5.Market size analysis, by Distribution Channel
10.4.3.UAE
10.4.3.1.Market size analysis, by Disease Type
10.4.3.2.Market size analysis, by Treatment Type
10.4.3.3.Market size analysis, by Drug Class Outlook
10.4.3.4.Market size analysis, by Route of Administration
10.4.3.5.Market size analysis, by Distribution Channel
10.4.4.South Africa
10.4.4.1.Market size analysis, by Disease Type
10.4.4.2.Market size analysis, by Treatment Type
10.4.4.3.Market size analysis, by Drug Class Outlook
10.4.4.4.Market size analysis, by Route of Administration
10.4.4.5.Market size analysis, by Distribution Channel
10.4.5.Rest of LAMEA
10.4.5.1.Market size analysis, by Disease Type
10.4.5.2.Market size analysis, by Treatment Type
10.4.5.3.Market size analysis, by Drug Class Outlook
10.4.5.4.Market size analysis, by Route of Administration
10.4.5.5.Market size analysis, by Distribution Channel
10.4.6.Research Dive Exclusive Insights
10.4.6.1.Market attractiveness
10.4.6.2.Competition heatmap
11.Competitive Landscape
11.1.Top winning strategies, 2021
11.1.1.By strategy
11.1.2.By year
11.2.Strategic overview
11.3.Market share analysis, 2021
12.Company Profiles
12.1.Novartis AG
12.1.1.Overview
12.1.2.Business segments
12.1.3.Product portfolio
12.1.4.Financial performance
12.1.5.Recent developments
12.1.6.SWOT analysis
12.2.Pfizer, Inc.
12.2.1.Overview
12.2.2.Business segments
12.2.3.Product portfolio
12.2.4.Financial performance
12.2.5.Recent developments
12.2.6.SWOT analysis
12.3.Mylan N.V.
12.3.1.Overview
12.3.2.Business segments
12.3.3.Product portfolio
12.3.4.Financial performance
12.3.5.Recent developments
12.3.6.SWOT analysis
12.4.F. Hoffmann La Roche Ltd.
12.4.1.Overview
12.4.2.Business segments
12.4.3.Product portfolio
12.4.4.Financial performance
12.4.5.Recent developments
12.4.6.SWOT analysis
12.5.Eli Lilly And Company
12.5.1.Overview
12.5.2.Business segments
12.5.3.Product portfolio
12.5.4.Financial performance
12.5.5.Recent developments
12.5.6.SWOT analysis
12.6.Merck & Co., Inc.
12.6.1.Overview
12.6.2.Business segments
12.6.3.Product portfolio
12.6.4.Financial performance
12.6.5.Recent developments
12.6.6.SWOT analysis
12.7.Teva Pharmaceutical Industries Ltd.
12.7.1.Overview
12.7.2.Business segments
12.7.3.Product portfolio
12.7.4.Financial performance
12.7.5.Recent developments
12.7.6.SWOT analysis
12.8.Celltrion Healthcare Co., Ltd.
12.8.1.Overview
12.8.2.Business segments
12.8.3.Product portfolio
12.8.4.Financial performance
12.8.5.Recent developments
12.8.6.SWOT analysis
12.9.Samsung Bioepis
12.9.1.Overview
12.9.2.Business segments
12.9.3.Product portfolio
12.9.4.Financial performance
12.9.5.Recent developments
12.9.6.SWOT analysis
12.10.Bristol Myers Squibb Company
12.10.1.Overview
12.10.2.Business segments
12.10.3.Product portfolio
12.10.4.Financial performance
12.10.5.Recent developments
12.10.6.SWOT analysis
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization
